Petition Piles Pressure On FDA Over Biosimilar Suffix

 
• By Dave Wallace

A citizen petition filed by biosimilars industry veteran Sarfaraz Niazi has once again urged the FDA to reconsider its approach on biosimilar naming, along with suggesting changes to language used by the regulator to describe biosimilars.

Suffix
Suffixes To Biosimilar Names Are Once Again In The Spotlight • Source: Shutterstock

More from Regulation

More from Policy & Regulation